About

Sean is an Operating Partner of CBC Group (formerly C-Bridge Capital) and the CEO of ABio-X holdings, a company created by CBC to focus on company incubation. Sean is also the co-founder and first CEO of Ensem Therapeutics, the co-founder and board director of RVAC Medicines, Jadeite Medicines and Kudo Biotechnology. In 2017, Sean co-founded Everest Medicines, and served as its CEO until 2020. While building Everest Medicines, Sean also incubated NiKang Therapeutics with its scientific co-founders, served as the CEO from 2017 to 2020 and the Chairman until 2021. Sean also served as the CBO for I-Mab Biopharma from the company’s inception in 2016 until early 2018. Prior to CBC, Sean was VP of Global Business Development at Simcere Pharmaceutical Group, and the President and Board Director at Simcere of America. Before joining Simcere, Sean was the Senior Director of Alternative Partnership, Evaluation & Expertise at Sanofi, where he led the externalization effort in Global R&D and managed the evaluation of acquisition/in-licensing opportunities. Prior to Sanofi, Sean was an Associate at New Leaf Venture Partners. Sean had worked in the pharmaceutical and diagnostic industries for over eight years at Aventis and Johnson & Johnson, before joining New Leaf.

Sean holds a PhD in Microbiology from the University of Virginia, an MBA with honor from the Wharton School of the University of Pennsylvania, and a BS in Microbiology from Nankai University, China.

Yunxiang joined MLAB  as a co-founder and CSO, responsible for defining MLAB’s pipeline and R&D strategy. He has over two decades of drug discovery with broad expertise in enzyme replacement therapy, drug delivery, bispecific antibody or bi-/multi-functional antibody fusion protein design, and AAV gene therapy development in various diseases areas ranging from lysosomal storage diseases, genetic metabolic and muscular dystrophies, autoimmune diseases, and immune-oncology. His longest career was at Genzyme/Sanofi where he was the head of muscle diseases and invented FDA/EMA approved drug Nexviazyme for the treatment of Pompe disease.

Prior to joining MLAB, Yunxiang served as the global head of CANbridge, responsible for strategic oversight of its gene therapy pipelines and external collaboration/partnership. Before CANbridge, Yunxiang was a SVP at Shenogen for biologics discovery and development.

Yunxiang earned his B.S. from Zhejiang University, M.S. from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, PhD at Miller School of Medicine at University of Miami, and completed his post-doc training at Washington University School of Medicine in St. Louis. He has co-authored about 30 publications and is a key inventor of over 15 issued patents and 5 pending patent applications.

Yangde was MLAB’s first employee. As the CTO/COO, he oversees MLAB’s technology platforms and daily business operations. Additionally, he contributes to pipeline initiation/progression and strategy implementation by closely collaborating with the management team and other stakeholders.

Before joining MLAB, Yangde served as the VP of Antibody Engineering at KLUS Pharma, concentrating on developing novel immunotherapies for cancer treatment. Prior to that, he held the position of VP of Antibody Discovery at Abpro, a company specializing in the development of T cell redirecting bispecific antibodies for cancer treatment. Yangde spent the majority of his career at Sanofi for nearly 20 years, with increasing responsibilities. As a Director at Sanofi’s US Biologics Research, he and his team were responsible for discovering novel therapeutic antibodies across various therapeutic areas. They have delivered multiple candidates to the company’s pipeline.

Yangde received his Ph.D. from Rutgers University, an M.S. from the Institute of Microbiology, Chinese Academy of Sciences, and a B.S. from Huazhong Agricultural University.